Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences total assets
Total assets on the balance sheet at the end of each period.
Korsana Biosciences's total assets was $6.93M at Jun 30, 2026. For fiscal 2025 it was $9.99M, up 4.3% from the year before. The highest annual figure on record is $186.48M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.99M | +4.3% |
| FY2024 | Dec 31, 2024 | $9.58M | -28.4% |
| FY2023 | Dec 31, 2023 | $13.37M | -26.0% |
| FY2022 | Dec 31, 2022 | $18.08M | -69.5% |
| FY2021 | Dec 31, 2021 | $59.33M | -48.6% |
| FY2020 | Dec 31, 2020 | $115.38M | -38.1% |
| FY2019 | Dec 31, 2019 | $186.48M | +2419.6% |
| FY2018 | Dec 31, 2018 | $7.40M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.93M | -26.0% |
| Q1 FY2026 | Mar 31, 2026 | $8.51M | -13.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.99M | +4.3% |
| Q3 FY2025 | Sep 30, 2025 | $10.42M | +17.0% |
| Q2 FY2025 | Jun 30, 2025 | $9.37M | -6.9% |
| Q1 FY2025 | Mar 31, 2025 | $9.85M | -13.3% |
| Q4 FY2024 | Dec 31, 2024 | $9.58M | -28.4% |
| Q3 FY2024 | Sep 30, 2024 | $8.90M | -41.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.07M | -0.3% |
| Q1 FY2024 | Mar 31, 2024 | $11.36M | -0.8% |
| Q4 FY2023 | Dec 31, 2023 | $13.37M | -26.0% |
| Q3 FY2023 | Sep 30, 2023 | $15.21M | -39.3% |
| Q2 FY2023 | Jun 30, 2023 | $10.10M | -71.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.46M | -75.4% |
| Q4 FY2022 | Dec 31, 2022 | $18.08M | -69.5% |
| Q3 FY2022 | Sep 30, 2022 | $25.05M | -63.0% |
| Q2 FY2022 | Jun 30, 2022 | $35.21M | -53.5% |
| Q1 FY2022 | Mar 31, 2022 | $46.53M | -53.5% |
| Q4 FY2021 | Dec 31, 2021 | $59.33M | -48.6% |
| Q3 FY2021 | Sep 30, 2021 | $67.74M | -48.4% |
| Q2 FY2021 | Jun 30, 2021 | $75.73M | -40.9% |
| Q1 FY2021 | Mar 31, 2021 | $99.97M | -28.6% |
| Q4 FY2020 | Dec 31, 2020 | $115.38M | -38.1% |
| Q3 FY2020 | Sep 30, 2020 | $131.40M | -37.3% |
| Q2 FY2020 | Jun 30, 2020 | $128.04M | -45.6% |
| Q1 FY2020 | Mar 31, 2020 | $140.03M | +1332.8% |
| Q4 FY2019 | Dec 31, 2019 | $186.48M | +2419.6% |
| Q3 FY2019 | Sep 30, 2019 | $209.70M | – |
| Q2 FY2019 | Jun 30, 2019 | $235.50M | – |
| Q1 FY2019 | Mar 31, 2019 | $9.77M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.40M | – |
See a number that looks wrong?